SCHEDULE: BlackRock Discloses 5.8% Stake in Eledon Pharmaceuticals

BlackRock, Inc. has reported beneficial ownership of 5.8% of Eledon Pharmaceuticals, Inc.'s common stock as of March 31, 2026.

Summary

• BlackRock, Inc. has filed a Schedule 13G, indicating its beneficial ownership of Eledon Pharmaceuticals, Inc. common stock.
• As of March 31, 2026, BlackRock beneficially owns 4,380,857 shares, representing 5.8% of the class.
• The filing specifies sole voting power for 4,324,348 shares and sole dispositive power for 4,380,857 shares.
• BlackRock, Inc. is organized in Delaware and is classified as a 'HC' (likely meaning Holding Company or a similar institutional classification) reporting person.
• The filing clarifies that this Schedule 13G reflects securities beneficially owned by certain reporting business units of BlackRock, Inc. and its subsidiaries and affiliates, and does not include securities owned by other disaggregated business units.
• No single person's interest in Eledon Pharmaceuticals, Inc. common stock exceeds five percent, according to the filing.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of institutional ownership and does not provide performance data or strategic insights into Eledon Pharmaceuticals itself.

Positives

• BlackRock's investment indicates confidence in Eledon Pharmaceuticals, potentially signaling institutional support.
• The filing confirms BlackRock's significant, though not controlling, stake, which could lead to increased liquidity or market interest in Eledon's stock.

Negatives

• The filing is a standard disclosure and does not contain operational or financial performance data for Eledon Pharmaceuticals, limiting insight into the company's health.
• BlackRock's role as a passive investor (as indicated by the 13G filing) means they are not actively seeking to control or influence the company's management or policies.

Risks

• The filing does not detail specific risks related to Eledon Pharmaceuticals' business operations or financial performance.
• The primary risk associated with this filing is the potential for BlackRock to alter its holdings, which could impact Eledon's stock price.

Future Outlook

This filing is a disclosure of current ownership and does not contain forward-looking statements or guidance regarding Eledon Pharmaceuticals, Inc.'s future performance.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the 'Reporting Business Units') of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release."
• "Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of Eledon Pharmaceuticals, Inc.. No one person's interest in the common stock of Eledon Pharmaceuticals, Inc. is more than five percent of the total outstanding common shares."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that BlackRock, Inc.'s filing of a Schedule 13G indicates a passive investment stake, common for large asset managers in the biotechnology and pharmaceutical sectors. This type of filing typically signifies that the investor does not intend to influence or control the issuer's management, but rather holds the shares as part of a diversified portfolio. The 5.8% stake suggests BlackRock views Eledon Pharmaceuticals as a potentially valuable holding within its investment universe.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's presence, which can be viewed positively for liquidity and potential future interest, but the passive nature of the holding means no immediate strategic influence is implied.
• Management of Eledon Pharmaceuticals: The passive nature of BlackRock's stake suggests no immediate pressure or influence on management decisions.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Monitor future filings by BlackRock, Inc. for any changes in beneficial ownership.
• Review Eledon Pharmaceuticals, Inc.'s own SEC filings for operational and financial updates.

Key Dates

Keywords

Eledon Pharmaceuticals, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Investment Management